2019 Parkinson Study Group Symposium and Training

摘要 拟议的为期三年的会议项目，以美国医学会的年度临床研究研讨会为中心 帕金森研究小组(PSG)和相关的年度会议活动，将促进教育和 培训早期研究人员，以确保最高质量的翻译和临床研究 继续为改善帕金森氏症和相关神经疾病的治疗而进行。 该项目目标将通过两个具体目标(SA)来实现。在SA#1中，PSG将展示其 第32届帕金森氏病的病因、发病机制和治疗年会 其他运动障碍“，与亨廷顿研究小组(HSG)合作，Dystonia研究 抽动症研究组(TSSG)、协作性共济失调组(CAG)和震颤 研究小组(TRG)于2019年4月6日星期六在亚利桑那州凤凰城举行第33届和第34届研讨会 此后每年一次。同行评审计划包括现场平台演示和海报演示 采用受众参与的格式。研讨会主题将有力地应对重大挑战。 以及寻求改善帕金森氏症和其他疾病患者治疗的机会 神经退行性疾病，主旨演讲传达补充神经生物学，临床 发展和病人的观点。2019年研讨会将讨论PD的革命性影响 遗传学，特别是GBA和LRRK2突变，与PD治疗的发展有关。SA#2是 旨在为早期临床研究人员提供运动障碍的多方面培训 对帕金森病临床研究的实用导向。选定的初级调查人员将参与几项 除研讨会外，开展新颖和互动的教育研究活动，包括a)直接 与帕金森基金会(Parkinson‘s Foundation)有经验的患者倡导者交流 研究倡导者)计划，以了解患者的意见如何有助于他们的研究，以及b)PSG 指导委员会的初级研究员技能研讨会，每年轮换主题跨越临床 研究项目开发、拨款提案撰写和新兴研究方法。朱尼尔 完成参与该项目的调查人员将得到更好的准备和动力 在临床神经学方面追求事业和严谨的研究。

Abstract The proposed three-year conference project, centered on the annual clinical research symposium of the Parkinson Study Group (PSG) and associated annual meeting activities, will foster the education and training of early stage investigators to ensure that the highest quality translational and clinical research continues to be conducted toward improved therapy for Parkinson's and related neurological disease. This project goal will be achieved through two specific aims (SAs). In SA #1, the PSG will present its “32nd Annual Symposium on the Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders” in collaboration with the Huntington Study Group (HSG), Dystonia Study Group (DSG), Tourette Syndrome Study Group (TSSG), Cooperative Ataxia Group (CAG), and Tremor Research Group (TRG) on Saturday, April 6, 2019 in Phoenix, AZ, and the 33rd and 34th symposia annually thereafter. The peer-reviewed program includes both platform and poster presentations in a live format with audience participation. The symposia themes will authoritatively address major challenges and opportunities in pursuit of improved treatment for people with Parkinson's and other neurodegenerative diseases, with keynote talks conveying complementary neurobiological, clinical development and patient perspectives. The 2019 Symposium will cover the revolutionary impact of PD genetics, and GBA and LRRK2 mutations in particularly, on PD therapeutics development. SA #2 is designed to provide early-stage clinical investigators with movement disorders training a multi-faceted practical orientation to PD clinical research. The selected junior investigators will participate in several novel and interactive, educational research activities in addition to the symposium, including a) direct exchange with experienced patient advocates of the Parkinson's Foundation's PAIR (Parkinson's Advocates in Research) program to learn how patient input can benefit their research, and b) the PSG Mentoring Committee's junior investigator skills workshop with annually rotating themes spanning clinical research project development, grant proposal writing, and emerging research methodologies. Junior investigators completing participation in the project will be substantially better prepared and motivated to pursue careers and rigorous studies in clinical neurology.